New hope for rare sarcoma: drug combo shows promise in trial
NCT ID NCT01391962
First seen Feb 02, 2026 · Last updated May 01, 2026 · Updated 13 times
Summary
This phase 2 trial tested two oral drugs, sunitinib and cediranib, in 34 patients with metastatic alveolar soft part sarcoma (ASPS), a rare cancer. Patients were randomly assigned to one drug, and if their disease worsened, they could switch to the other. The goal was to see if these drugs could shrink tumors or slow progression. The study found that both drugs showed some activity, offering a potential treatment option for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA, ALVEOLAR SOFT PART are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.